Symbols / KPTI Stock $9.17 +2.57% Karyopharm Therapeutics Inc.
KPTI (Stock) Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Market Cap | 206.72M | Enterprise Value | — | Income | — | Sales | — | Book/sh | — | Cash/sh | — |
| Dividend Yield | — | Payout | — | Employees | — | IPO | — | P/E | — | Forward P/E | — |
| PEG | — | P/S | — | P/B | — | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | — | Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | — | EPS next Y | — |
| EPS Growth | — | Revenue Growth | — | Earnings | — | ROA | — | ROE | — | ROIC | — |
| Gross Margin | — | Oper. Margin | — | Profit Margin | — | Shs Outstand | — | Shs Float | — | Short Float | — |
| Short Ratio | — | Short Interest | — | 52W High | — | 52W Low | — | Beta | — | Avg Volume | — |
| Volume | — | Target Price | — | Recom | — | Prev Close | $8.94 | Price | $9.17 | Change | 2.57% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN hu, 23 Apr 2026 03
- Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan Wed, 22 Apr 2026 20
- Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below Expectations - Pricing Power - Xã Thanh Hà hu, 23 Apr 2026 03
- Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance Fri, 27 Mar 2026 07
- KPTI Stock Price, Quote & Chart | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill Fri, 17 Apr 2026 07
- Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire ue, 24 Mar 2026 07
- $KPTI stock is up 12% today. Here's what we see in our data. - Quiver Quantitative ue, 07 Apr 2026 07
- Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - qz.com Fri, 27 Mar 2026 07
- KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Zacks Investment Research Wed, 25 Mar 2026 07
- Late-breaking ASCO slot for Karyopharm's myelofibrosis Phase 3 study - Stock Titan ue, 21 Apr 2026 14
- $KPTI stock is down 8% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PR Newswire hu, 12 Feb 2026 08
- New myelofibrosis drug combo shrank spleens in half of patients - Stock Titan ue, 24 Mar 2026 07
- Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade - Yahoo Finance Wed, 18 Feb 2026 08
- How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations - Yahoo Finance Sun, 22 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
146.07
+0.57%
|
145.24
-0.55%
|
146.03
-7.03%
|
157.07
|
| Operating Revenue |
|
146.07
+0.57%
|
145.24
-0.55%
|
146.03
-7.03%
|
157.07
|
| Cost Of Revenue |
|
5.95
-0.97%
|
6.01
+21.55%
|
4.94
-5.20%
|
5.21
|
| Reconciled Cost Of Revenue |
|
5.95
-0.97%
|
6.01
+21.55%
|
4.94
-5.20%
|
5.21
|
| Gross Profit |
|
140.12
+0.64%
|
139.23
-1.32%
|
141.09
-7.09%
|
151.86
|
| Operating Expense |
|
230.82
-10.77%
|
258.67
-4.42%
|
270.63
-7.97%
|
294.06
|
| Research And Development |
|
125.62
-12.30%
|
143.23
+3.23%
|
138.75
-6.67%
|
148.66
|
| Selling General And Administration |
|
105.21
-8.86%
|
115.44
-12.47%
|
131.88
-9.30%
|
145.40
|
| General And Administrative Expense |
|
105.21
-8.86%
|
115.44
-12.47%
|
131.88
-9.30%
|
145.40
|
| Salaries And Wages |
|
61.34
-13.69%
|
71.07
-12.56%
|
81.28
-8.67%
|
88.99
|
| Other Gand A |
|
43.86
-1.14%
|
44.37
-12.32%
|
50.61
-10.29%
|
56.41
|
| Total Expenses |
|
236.77
-10.54%
|
264.68
-3.95%
|
275.57
-7.92%
|
299.28
|
| Operating Income |
|
-90.71
+24.06%
|
-119.44
+7.79%
|
-129.54
+8.90%
|
-142.20
|
| Total Operating Income As Reported |
|
-90.71
+24.06%
|
-119.44
+7.79%
|
-129.54
+8.90%
|
-142.20
|
| EBITDA |
|
-149.85
-288.18%
|
-38.60
+67.40%
|
-118.42
+14.99%
|
-139.31
|
| Normalized EBITDA |
|
-87.49
-5.02%
|
-83.31
+29.65%
|
-118.42
+14.99%
|
-139.31
|
| Reconciled Depreciation |
|
0.30
-12.94%
|
0.34
-35.85%
|
0.53
-14.65%
|
0.62
|
| EBIT |
|
-150.15
-285.56%
|
-38.94
+67.26%
|
-118.95
+14.99%
|
-139.93
|
| Total Unusual Items |
|
-62.37
-239.51%
|
44.70
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-62.37
-239.51%
|
44.70
|
0.00
|
0.00
|
| Special Income Charges |
|
-62.37
-239.51%
|
44.70
|
0.00
|
0.00
|
| Other Special Charges |
|
62.37
+239.51%
|
-44.70
|
—
|
—
|
| Net Income |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Pretax Income |
|
-196.00
-156.66%
|
-76.36
+46.51%
|
-142.78
+13.43%
|
-164.92
|
| Net Non Operating Interest Income Expense |
|
-43.08
-43.48%
|
-30.02
-133.09%
|
-12.88
+43.10%
|
-22.64
|
| Interest Expense Non Operating |
|
45.85
+22.52%
|
37.42
+57.08%
|
23.82
-4.69%
|
25.00
|
| Net Interest Income |
|
-43.08
-43.48%
|
-30.02
-133.09%
|
-12.88
+43.10%
|
-22.64
|
| Interest Expense |
|
45.85
+22.52%
|
37.42
+57.08%
|
23.82
-4.69%
|
25.00
|
| Interest Income Non Operating |
|
2.77
-62.53%
|
7.40
-32.38%
|
10.94
+363.88%
|
2.36
|
| Interest Income |
|
2.77
-62.53%
|
7.40
-32.38%
|
10.94
+363.88%
|
2.36
|
| Other Income Expense |
|
-62.21
-185.11%
|
73.10
+20633.71%
|
-0.36
-328.92%
|
-0.08
|
| Other Non Operating Income Expenses |
|
0.15
-99.46%
|
28.40
+8076.97%
|
-0.36
-328.92%
|
-0.08
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-0.10
|
| Tax Provision |
|
0.04
-24.56%
|
0.06
-82.35%
|
0.32
-12.47%
|
0.37
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-13.10
-239.51%
|
9.39
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Net Income From Continuing Operation Net Minority Interest |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Net Income From Continuing And Discontinued Operation |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Net Income Continuous Operations |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Normalized Income |
|
-146.77
-31.35%
|
-111.74
+21.92%
|
-143.10
+13.43%
|
-165.29
|
| Net Income Common Stockholders |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Diluted EPS |
|
-17.93
-28.53%
|
-13.95
+25.76%
|
-18.79
+37.99%
|
-30.30
|
| Basic EPS |
|
-17.93
-89.74%
|
-9.45
+49.71%
|
-18.79
+37.99%
|
-30.30
|
| Basic Average Shares |
|
10.94
+34.60%
|
8.12
+6.67%
|
7.62
+39.54%
|
5.46
|
| Diluted Average Shares |
|
10.94
+29.35%
|
8.45
+11.00%
|
7.62
+39.54%
|
5.46
|
| Diluted NI Availto Com Stockholders |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
240.44
|
| Current Assets |
|
233.92
|
| Cash Cash Equivalents And Short Term Investments |
|
191.44
|
| Cash And Cash Equivalents |
|
52.23
|
| Other Short Term Investments |
|
139.21
|
| Receivables |
|
26.96
|
| Accounts Receivable |
|
26.96
|
| Inventory |
|
3.04
|
| Raw Materials |
|
0.55
|
| Work In Process |
|
1.73
|
| Finished Goods |
|
0.76
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
0.66
|
| Other Current Assets |
|
11.81
|
| Total Non Current Assets |
|
6.52
|
| Net PPE |
|
4.88
|
| Gross PPE |
|
11.45
|
| Accumulated Depreciation |
|
-6.57
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.46
|
| Other Properties |
|
5.11
|
| Leases |
|
4.88
|
| Investments And Advances |
|
—
|
| Other Non Current Assets |
|
1.64
|
| Total Liabilities Net Minority Interest |
|
376.64
|
| Current Liabilities |
|
69.48
|
| Payables And Accrued Expenses |
|
48.01
|
| Payables |
|
3.12
|
| Accounts Payable |
|
3.12
|
| Current Accrued Expenses |
|
44.88
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
16.51
|
| Current Debt And Capital Lease Obligation |
|
3.31
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
3.31
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Other Current Liabilities |
|
1.65
|
| Total Non Current Liabilities Net Minority Interest |
|
307.17
|
| Long Term Debt And Capital Lease Obligation |
|
173.71
|
| Long Term Debt |
|
170.92
|
| Long Term Capital Lease Obligation |
|
2.79
|
| Non Current Deferred Liabilities |
|
132.48
|
| Other Non Current Liabilities |
|
0.98
|
| Stockholders Equity |
|
-136.21
|
| Common Stock Equity |
|
-136.21
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
7.66
|
| Ordinary Shares Number |
|
7.66
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
1,350.98
|
| Retained Earnings |
|
-1,487.04
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.16
|
| Other Equity Adjustments |
|
-0.16
|
| Total Equity Gross Minority Interest |
|
-136.21
|
| Total Capitalization |
|
34.71
|
| Working Capital |
|
164.44
|
| Invested Capital |
|
34.71
|
| Total Debt |
|
177.02
|
| Net Debt |
|
118.69
|
| Capital Lease Obligations |
|
6.10
|
| Net Tangible Assets |
|
-136.21
|
| Tangible Book Value |
|
-136.21
|
| Derivative Product Liabilities |
|
0.00
|
| Interest Payable |
|
13.45
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-75.37
+40.88%
|
-127.49
-37.49%
|
-92.72
+38.00%
|
-149.55
|
| Cash Flow From Continuing Operating Activities |
|
-75.37
+40.88%
|
-127.49
-37.49%
|
-92.72
+38.00%
|
-149.55
|
| Net Income From Continuing Operations |
|
-196.04
-156.52%
|
-76.42
+46.60%
|
-143.10
+13.43%
|
-165.29
|
| Depreciation Amortization Depletion |
|
0.30
-12.94%
|
0.34
-35.85%
|
0.53
-14.65%
|
0.62
|
| Depreciation And Amortization |
|
0.30
-12.94%
|
0.34
-35.85%
|
0.53
-14.65%
|
0.62
|
| Other Non Cash Items |
|
16.80
+163.84%
|
6.37
+682.43%
|
0.81
+0.25%
|
0.81
|
| Stock Based Compensation |
|
14.05
-23.75%
|
18.43
-15.12%
|
21.71
-38.67%
|
35.40
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
61.66
+184.01%
|
-73.39
|
—
|
-0.28
|
| Gain Loss On Investment Securities |
|
-0.71
+97.54%
|
-28.69
|
—
|
-0.28
|
| Change In Working Capital |
|
28.27
+9461.59%
|
-0.30
-100.96%
|
31.42
+257.19%
|
-19.99
|
| Change In Receivables |
|
4.59
+220.61%
|
-3.80
-118.90%
|
20.12
+495.83%
|
-5.08
|
| Changes In Account Receivables |
|
4.59
+220.61%
|
-3.80
-118.90%
|
20.12
+495.83%
|
-5.08
|
| Change In Inventory |
|
0.70
+141.33%
|
-1.70
-243.61%
|
1.18
+1100.85%
|
-0.12
|
| Change In Prepaid Assets |
|
4.13
+1055.09%
|
-0.43
-106.47%
|
6.67
+215.43%
|
-5.78
|
| Change In Payables And Accrued Expense |
|
17.96
+190.36%
|
6.18
+42.12%
|
4.35
+152.02%
|
-8.37
|
| Change In Accrued Expense |
|
19.06
+353.77%
|
4.20
+4.97%
|
4.00
+141.97%
|
-9.54
|
| Change In Payable |
|
-1.10
-155.65%
|
1.98
+466.86%
|
0.35
-70.09%
|
1.17
|
| Change In Account Payable |
|
-1.10
-155.65%
|
1.98
+466.86%
|
0.35
-70.09%
|
1.17
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
1.34
+183.08%
|
-1.61
-181.96%
|
1.96
+16.99%
|
1.68
|
| Change In Other Current Liabilities |
|
-0.44
-141.60%
|
1.05
+136.66%
|
-2.87
-24.01%
|
-2.32
|
| Investing Cash Flow |
|
43.38
-54.57%
|
95.47
+1102.43%
|
7.94
+107.62%
|
-104.26
|
| Cash Flow From Continuing Investing Activities |
|
43.38
-54.57%
|
95.47
+1102.43%
|
7.94
+107.62%
|
-104.26
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.14
|
0.00
+100.00%
|
-0.12
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.14
|
0.00
+100.00%
|
-0.12
|
| Capital Expenditure |
|
—
|
-0.14
|
—
|
-0.12
|
| Net Investment Purchase And Sale |
|
43.38
-54.63%
|
95.61
+1104.22%
|
7.94
+107.62%
|
-104.14
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-58.82
+63.04%
|
-159.15
+29.58%
|
-226.02
|
| Sale Of Investment |
|
43.38
-71.91%
|
154.44
-7.57%
|
167.09
+37.10%
|
121.88
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
30.05
-27.85%
|
41.65
+3605.16%
|
1.12
-99.42%
|
193.74
|
| Cash Flow From Continuing Financing Activities |
|
30.05
-27.85%
|
41.65
+3605.16%
|
1.12
-99.42%
|
193.74
|
| Net Issuance Payments Of Debt |
|
27.00
-67.59%
|
83.30
|
0.00
|
0.00
|
| Issuance Of Debt |
|
27.25
-67.29%
|
83.30
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-0.25
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
27.25
-67.29%
|
83.30
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-0.25
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
27.00
-67.59%
|
83.30
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
8.75
|
0.00
|
0.00
-100.00%
|
189.76
|
| Proceeds From Stock Option Exercised |
|
0.76
-47.59%
|
1.45
+29.18%
|
1.12
-71.74%
|
3.98
|
| Net Other Financing Charges |
|
-6.46
+85.01%
|
-43.11
|
—
|
—
|
| Changes In Cash |
|
-1.94
-120.17%
|
9.63
+111.51%
|
-83.66
-39.26%
|
-60.07
|
| Effect Of Exchange Rate Changes |
|
0.02
+281.82%
|
-0.01
+67.65%
|
-0.03
+93.03%
|
-0.49
|
| Beginning Cash Position |
|
62.81
+18.09%
|
53.19
-61.14%
|
136.88
-30.67%
|
197.44
|
| End Cash Position |
|
60.89
-3.06%
|
62.81
+18.09%
|
53.19
-61.14%
|
136.88
|
| Free Cash Flow |
|
-75.37
+40.95%
|
-127.63
-37.64%
|
-92.72
+38.05%
|
-149.67
|
| Interest Paid Supplemental Data |
|
14.38
-62.74%
|
38.59
+81.81%
|
21.23
-38.38%
|
34.45
|
| Amortization Of Securities |
|
-0.41
+83.63%
|
-2.50
+38.90%
|
-4.10
-396.73%
|
-0.82
|
| Common Stock Issuance |
|
8.75
|
0.00
|
0.00
-100.00%
|
189.76
|
| Issuance Of Capital Stock |
|
8.75
|
0.00
|
0.00
-100.00%
|
189.76
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 8-K2026-03-27 View
- 8-K2026-03-24 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 8-K2026-03-03 View
- 8-K2026-02-19 View
- 42026-02-19 View
- 10-K2026-02-13 View
- 8-K2026-02-12 View
- 42026-02-09 View
- 42026-02-04 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|